Rain Therapeutics

OverviewSuggest Edit

Rain Therapeutics is a biotechnology company focused on developing small molecule targeted therapeutics for cancer patients. Its approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology.

TypePublic
Founded2017
HQNewark, CA, US
Websiterainthera.com

Latest Updates

Employees (est.) (Apr 2021)17
Share Price (Jun 2022)$2.3(+5%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Rain Therapeutics

Avanish Vellanki

Avanish Vellanki

CEO and Cofounder, Chairman
Robert Doebele

Robert Doebele

President, Chief Scientific Officer & Cofounder
Richard Bryce

Richard Bryce

Chief Medical Officer
Lucio Tozzi

Lucio Tozzi

Senior Vice President, Clinical Operations
Vijaya Tirunagaru

Vijaya Tirunagaru

Senior Vice President and Head of Research
Allan Wagman

Allan Wagman

Vice President, Chemistry
Show more

Rain Therapeutics Office Locations

Rain Therapeutics has an office in Newark
Newark, CA, US (HQ)
8000 Jarvis Ave #204
Show all (1)

Rain Therapeutics Financials and Metrics

Rain Therapeutics Revenue

USD

Net income (Q1, 2021)

(6.8m)

EBIT (Q1, 2021)

(6.8m)

Market capitalization (17-Jun-2022)

61.4m

Closing stock price (17-Jun-2022)

2.3

Cash (31-Mar-2021)

53.1m

EV

8.8m
Rain Therapeutics's current market capitalization is $61.4 m.
Annual
USDFY, 2019FY, 2020

General and administrative expense

3.5m3.6m

R&D expense

7.3m15.4m

Operating expense total

10.8m19.0m

EBIT

(10.8m)(19.0m)
Quarterly
USDQ1, 2021

General and administrative expense

1.5m

R&D expense

5.3m

Operating expense total

6.8m

EBIT

(6.8m)
Annual
USDFY, 2019FY, 2020

Cash

5.8m58.9m

Prepaid Expenses

480.0k662.0k

PP&E

127.0k99.0k

Total Assets

7.4m61.1k
Quarterly
USDQ1, 2021

Cash

53.1m

Prepaid Expenses

702.0k

Current Assets

53.8m

PP&E

113.0k
Annual
USDFY, 2019FY, 2020

Net Income

(10.9m)(21.1m)

Depreciation and Amortization

28.0k52.0k

Accounts Payable

(249.0k)555.0k

Cash From Operating Activities

(11.2m)(11.2m)
Quarterly
USDQ1, 2021

Net Income

(6.8m)

Depreciation and Amortization

15.0k

Accounts Payable

573.0k

Cash From Operating Activities

(4.9m)
USDFY, 2019

Debt/Assets

0.1 x

Financial Leverage

-0.4 x
Show all financial metrics

Rain Therapeutics Operating Metrics

Apr, 2021

Office Space Leased, sq. ft.

3.9 k

Rain Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Rain Therapeutics Online and Social Media Presence

Embed Graph

Rain Therapeutics News and Updates

Rain Therapeutics to Present on Milademetan at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

NEWARK, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), ("Rain"), a late-stage biotechnology company developing precision oncology therapeutics, today announced it will be presenting three posters highlighting its oral mouse double minute 2 (MDM2) inhibitor, milad…

Rain Therapeutics Announces a Poster Presentation and Trials In Progress at the American Association for Cancer Research (AACR) Annual Meeting 2022

NEWARK, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced a poster presentation and two trials in progress at the upcoming American Association for Cancer Research (AACR) An…

Rain Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Highlights of Recent Progress on March 3, 2022

NEWARK, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will report financial results for the fourth quarter and full year ended December 31, 2021 and highlights of rece…

Rain Therapeutics Continues to Strengthen its Leadership Team with Key Appointments

– Industry veterans from Loxo/Lilly, Gilead, Seagen and AltruBio join Rain to expand clinical and regulatory operations –

Rain Therapeutics to Present at SVB Leerink Global Healthcare Conference

NEWARK, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will provide a corporate overview f…

Rain Therapeutics to Present at Upcoming Virtual Investor Conferences

B. Riley Securities virtual presentation scheduled for January 27th at 3:30 pm ET
Show more

Rain Therapeutics Frequently Asked Questions

  • When was Rain Therapeutics founded?

    Rain Therapeutics was founded in 2017.

  • Who are Rain Therapeutics key executives?

    Rain Therapeutics's key executives are Avanish Vellanki, Robert Doebele and Richard Bryce.

  • How many employees does Rain Therapeutics have?

    Rain Therapeutics has 17 employees.

  • Who are Rain Therapeutics competitors?

    Competitors of Rain Therapeutics include Enara Bio, BioNTech and Scorpion Therapeutics.

  • Where is Rain Therapeutics headquarters?

    Rain Therapeutics headquarters is located at 8000 Jarvis Ave #204, Newark.

  • Where are Rain Therapeutics offices?

    Rain Therapeutics has an office in Newark.

  • How many offices does Rain Therapeutics have?

    Rain Therapeutics has 1 office.